278 related articles for article (PubMed ID: 10735889)
1. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
Linderholm B; Grankvist K; Wilking N; Johansson M; Tavelin B; Henriksson R
J Clin Oncol; 2000 Apr; 18(7):1423-31. PubMed ID: 10735889
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
3. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
Linderholm B; Tavelin B; Grankvist K; Henriksson R
Br J Cancer; 1999 Oct; 81(4):727-32. PubMed ID: 10574263
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
Gasparini G; Toi M; Gion M; Verderio P; Dittadi R; Hanatani M; Matsubara I; Vinante O; Bonoldi E; Boracchi P; Gatti C; Suzuki H; Tominaga T
J Natl Cancer Inst; 1997 Jan; 89(2):139-47. PubMed ID: 8998183
[TBL] [Abstract][Full Text] [Related]
5. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma.
Linderholm B; Lindh B; Tavelin B; Grankvist K; Henriksson R
Int J Cancer; 2000 Jan; 89(1):51-62. PubMed ID: 10719731
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.
Gasparini G; Toi M; Biganzoli E; Dittadi R; Fanelli M; Morabito A; Boracchi P; Gion M
Oncology; 2001; 60(1):72-80. PubMed ID: 11150912
[TBL] [Abstract][Full Text] [Related]
7. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
[TBL] [Abstract][Full Text] [Related]
8. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.
Linderholm B; Tavelin B; Grankvist K; Henriksson R
J Clin Oncol; 1998 Sep; 16(9):3121-8. PubMed ID: 9738584
[TBL] [Abstract][Full Text] [Related]
10. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.
Linderholm BK; Lindahl T; Holmberg L; Klaar S; Lennerstrand J; Henriksson R; Bergh J
Cancer Res; 2001 Mar; 61(5):2256-60. PubMed ID: 11280795
[TBL] [Abstract][Full Text] [Related]
11. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients.
Manders P; Sweep FC; Tjan-Heijnen VC; Geurts-Moespot A; van Tienoven DT; Foekens JA; Span PN; Bussink J; Beex LV
Clin Cancer Res; 2003 Dec; 9(17):6363-70. PubMed ID: 14695136
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
14. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
16. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
[TBL] [Abstract][Full Text] [Related]
17. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
18. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
Pohl G; Rudas M; Dietze O; Lax S; Markis E; Pirker R; Zielinski CC; Hausmaninger H; Kubista E; Samonigg H; Jakesz R; Filipits M
J Clin Oncol; 2003 Oct; 21(19):3594-600. PubMed ID: 14512390
[TBL] [Abstract][Full Text] [Related]
19. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Eppenberger U; Kueng W; Schlaeppi JM; Roesel JL; Benz C; Mueller H; Matter A; Zuber M; Luescher K; Litschgi M; Schmitt M; Foekens JA; Eppenberger-Castori S
J Clin Oncol; 1998 Sep; 16(9):3129-36. PubMed ID: 9738585
[TBL] [Abstract][Full Text] [Related]
20. [The prognostic value of vascular endothelial growth factor in breast cancer].
Jing J; Zhao Y; Li H; Zhang S; Shi Z
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):566-8. PubMed ID: 12528550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
